Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941222 | 0.98 | MAPT (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL2795198 | 0.98 | MAPT (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL497034 | 0.95 | MAPT (0.37) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL6699994 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL8420655 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL23661069 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL11110396 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL497507 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL23486255 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD | |
| SCHEMBL8992014 | 0.93 | ALDH1A1 (0.35) | MAPTALDH1A1USP2INMTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4716172-A | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | MCNEILAB, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0241292-A2 | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | McNeilab, Inc. (US) | 1987-10-14 | — | — | EP | claimed |
| WO-2024034669-A1 | SILANE COMPOUND | ダイキン工業株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023188842-A1 | POLYETHER NITRILE FILM AND METHOD FOR PRODUCING POLYETHER NITRILE FILM | 東レ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-3642284-A1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | Wacker Chemie AG (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3619274-A1 | AQUEOUS DISPERSIONS OF ORGANOSILICON COMPOUNDS | Wacker Chemie AG (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-10544166-B2 | Compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2020-01-28 | — | — | US | disclosed |
| WO-2019052660-A1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2019-03-21 | — | — | WO | disclosed |
| US-20180186817-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-07-05 | — | — | US | disclosed |
| EP-3259300-A1 | METHOD FOR PRODUCING POLYCARBONATES BY TRANSESTERIFICATION OF DITHIOCARBONATES OR THE SELENIUM ANALOGUES THEREOF WITH BISPHENOLS | Covestro Deutschland AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| CN-103649084-B | 1,4 disubstituted 1,2,3 triazoles, methods for making them and its diagnostic and therapeutic use | 国家科学研究中心 | 2017-03-29 | — | — | CN | disclosed |
| EP-0431605-A2 | 1-Azabicyclo[m.n.O]alkane derivatives, their salts and process for preparing them | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4916223-A | ALPAH 2-ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4831035-A | Substituted hexahydroarylquinolizines | MERCK & CO., INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0259092-A1 | Substituted hexahydroarylquinolizines | MERCK & CO. INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4716172-A | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | MCNEILAB, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4716172-A | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | MCNEILAB, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4716172-A | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | MCNEILAB, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0241292-A2 | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | McNeilab, Inc. (US) | 1987-10-14 | — | — | EP | disclosed |
| EP-0241292-A2 | 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates | McNeilab, Inc. (US) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186817-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | BLVRB, CDYL, CRY1 | MAPT 277/4885ALDH1A1 836/4885USP2 972/4885 |
| US-10544166-B2 | Compound and color conversion film comprising same | BLVRB, CDYL, CRY1 | MAPT 277/4885ALDH1A1 836/4885USP2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.